ALKERMES | ALKS - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 9.39B 4.16B 2026-03
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 5.28B 1.99B 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
Heron Therapeutics USD 26.12M 2.53M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
J&J USD 21.69B 1.98B 2026-03
Malin Corporation EUR 62.1M 26.4M 2024-12
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Otsuka Holdings JPY 534.64B 123.53B 2025-12
Pfizer USD 1.7B 561M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03